Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$211.17 USD

211.17
2,255,897

-16.27 (-7.15%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $210.00 -1.17 (-0.55%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance

by Zacks Equity Research

FDA accepts Biogen's (BIIB) partner Eisai's sBLA for a maintenance intravenous dosing version of Alzheimer's drug Leqembi. The final FDA decision is expected on Jan 25, 2025.

Why Is CRISPR Therapeutics (CRSP) Up 12% Since Last Earnings Report?

by Zacks Equity Research

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates

by Zacks Equity Research

GSK and Biogen (BIIB) are in the spotlight following litigation updates and drug approval, respectively.

Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?

by Zacks Equity Research

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Biogen Inc. (BIIB) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Denali's (DNLI) Candidate Selected for FDA's START Pilot Program

by Zacks Equity Research

Denali's (DNLI) DNL126, an investigational enzyme replacement therapy, gets selected for the START Pilot Program, intended to accelerate the development of rare disease therapies.

Repligen (RGEN) Down 10.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody

by Zacks Equity Research

Biogen's (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe

Qiagen (QGEN) Up 1.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Biogen (BIIB) Up 7.7% Since Last Earnings Report?

by Zacks Equity Research

Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics

by Zacks Equity Research

Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics are part of the Zacks top Analyst Blog.

Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News

by Zacks Equity Research

Biogen (BIIB) and PTC Therapeutics, Inc. (PTCT) are in the spotlight following acquisition news and regulatory updates, respectively.

Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline

by Zacks Equity Research

Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.

Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study

by Zacks Equity Research

The FDA removes the partial clinical hold on Larimar's (LRMR) nomlabofusp clinical program for the treatment of patients with Friedreich's Ataxia.

Why Biogen Inc. (BIIB) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Ionis (IONS), Biogen Down on Ending Development of ALS Drug

by Zacks Equity Research

Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.

Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector

by Zacks Equity Research

Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.

Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Ionis (IONS) posts mixed first-quarter 2024 results. The company continues to focus on pipeline development.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus

by Zacks Equity Research

Denali (DNLI) Q1 loss narrows year over year due to lower expenses despite nil revenues.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates

by Zacks Equity Research

Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.

The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals

by Zacks Equity Research

Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.

Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX

by Zacks Equity Research

Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.